[ad_1]
The pharmaceutical company Roche and its US partner Regeneron have obtained positive data with their corona antibody cocktail.
This reduced viral load and symptom relief time in non-hospitalized COVID-19 patients. In addition, the cocktail reduced the number of visits to the doctor.
Data on the research antibody cocktail “REGN-COV2” unveiled on Wednesday comes from a Phase I / II / III study called “seamless.” This is part of a larger program that also includes studies on treating hospital patients and preventing infections in people who have had contact with COVID-19 patients.
(Monitor)Combining new reverse barrier convertibles
The treatment has been shown to be particularly effective in patients who did not show their own effective immune response, Roche said. This suggests that REGN-COV2 could be a therapeutic surrogate for the natural immune response.
Roche and Regeneron have already started discussing the results with regulatory authorities. The studies would continue in parallel.
In August, Roche and Regeneron announced that they would jointly develop, manufacture and sell the Regeneron antibody cocktail around the world. The aim of the cooperation is also, in case of approval, to significantly increase the manufacturing capacity.
Roche shares temporarily fell 0.73 percent to 317.85 Swiss francs in Swiss trading.
hr / ra
Basel (awp)
